Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins - Wikidata - awgldk - TriplyDB

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

http://www.wikidata.org/entity/Q36726112

about

Targeting the insulin growth factor receptor 1 Targeting the PI3K signaling pathway in cancer The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy Combating acquired resistance to tyrosine kinase inhibitors in lung cancer Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.IGF-IR Targeted Therapy: Past, Present and Future The phosphoinositide 3-kinase pathway and therapy resistance in cancer A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation The quest to overcome resistance to EGFR-targeted therapies in cancer.Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.Receptor tyrosine kinase coactivation networks in cancer Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma Role of receptor tyrosine kinases and their ligands in glioblastoma.Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.Mammary gland growth factors: roles in normal development and in cancer.

P2860

Q24633750-E4D58806-1065-429C-B392-15DFD80FBC92 Q24647554-23A39DF8-B403-4658-8D46-20A5B1B085E9 Q26777125-051367BF-2572-4563-A03A-CBE89D393461 Q26801886-0A317CD5-0B40-4ECE-822A-80D0405F6818 Q26824462-B7E40487-4E4B-4D1F-8129-B8091417FDA9 Q26824877-45070A2B-102F-45B3-9B70-EA2E7B65646A Q26852215-BF3E92B5-25D4-4628-9791-7945C23857B8 Q27851610-95791E4E-A56A-4CE2-B1E7-0F4665E49DDD Q27851628-1DF7C697-A894-4EC1-9194-1EE004527E10 Q27851633-A182307A-B5E8-4763-9D75-864FEE3D5C58 Q27851674-B3B5FA16-FD40-4494-BC4A-D29B0F770D06 Q27852235-D1668641-0971-49C4-BB00-B8A37800A53A Q28082127-CF528AA9-05FA-4E95-B2BE-3EEC062B50A6 Q28082811-37A6231F-DE30-4ED7-8177-F80A054C563D Q28480605-481C5939-D046-468C-9A40-616A4EC8DE05 Q28481370-84776075-E5D0-470D-BA79-4EC22C7B59BA Q28537891-40206410-4F4B-41D9-BFB6-4649B8C89654 Q28541175-40123238-D444-4C97-B88E-EBA884530F3D Q28553420-20B9D92A-EF2B-43FE-A790-7F9FB9F28996 Q30424348-71305B98-4BBA-4E90-94E3-8EBCA870AD2C Q30502341-7078434A-ED01-4C71-8C73-0ECD331E479F Q33523195-61349820-C412-4B36-BA12-550FC78ACA06 Q33558069-72347BBF-3971-4C3D-A6DB-29F256A27DCD Q33601653-EBED37B2-976C-40CC-A323-26CC93E78C31 Q33605906-CE966135-76E9-4303-AD00-2D82EA43C278 Q33699007-F99DCD85-FC09-45F3-87F5-A88A96F2D4BE Q33725976-FA2666B1-1F30-4635-840B-2D0277C3C0E3 Q33770265-F198B961-D570-43D5-9F43-222AB5AE395D Q33777423-B6003D9B-92EC-4F8D-B73B-F6692D156F3D Q33778905-8977C837-A3AF-4AF9-BEDA-083EE79D2BF3 Q33828409-9FB444F1-3B4D-45D2-ADAE-8A19FE668417 Q33834851-548B602E-FD25-46EF-B999-95EDAE920292 Q33842810-65F725BB-3E64-49DE-9237-4D7062FD229D Q33843662-E0DC2A12-6591-4AD3-9707-3F39113D9BE9 Q33871842-EE9C7619-198E-4006-8E04-F39E1BECD3E5 Q33875560-16E9E5C2-2250-40DE-B733-A56EA93CCC82 Q33883849-FB76CD80-13DB-4560-99C7-E99EC157C2E7 Q33935045-B8E8BE3E-60E3-4C68-8C96-3145A5424281 Q33979359-509E131F-12A7-4EA6-8BC2-2B670098E535 Q34014659-F662367C-40EA-48E6-8B2C-F221DC84F8E8

P2860

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

http://www.wikidata.org/entity/Q36726112

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Acquired resistance to EGFR ty ...... y loss of IGF-binding proteins

@ast

Acquired resistance to EGFR ty ...... y loss of IGF-binding proteins

@en

type

label

Acquired resistance to EGFR ty ...... y loss of IGF-binding proteins

@ast

Acquired resistance to EGFR ty ...... y loss of IGF-binding proteins

@en

prefLabel

Acquired resistance to EGFR ty ...... y loss of IGF-binding proteins

@ast

Acquired resistance to EGFR ty ...... y loss of IGF-binding proteins

@en

P1433

Q36726112-410F9271-953C-48E2-B917-51EAC633ECC7

P1476

Q36726112-8ADB501D-E81C-440E-8076-22058FEBF544

P2093

Q36726112-0D9FD71F-4A9E-49C4-AEAF-3ED567494C88

Q36726112-1CAB2F28-BC9F-4C63-AC71-5263390FDC36

Q36726112-5703E294-F6AA-410F-90FB-289202F0CAED

Q36726112-58EF3B2E-A09B-4AE5-85B0-E90CC32B1B2D

Q36726112-5C6E082E-786B-4414-9122-CA81F75AFD2E

Q36726112-695F0BD4-B280-4F62-9903-B402D4071EE9

Q36726112-87CCEFD3-1639-4A48-9D0E-D01E5E6696CB

Q36726112-8E52C95C-8F1F-4049-B7F9-1B2AD285620F

Q36726112-ABD07012-8AF4-4E81-9FB0-A0B6EA938EB3

Q36726112-DEACCD0C-30B2-4A25-961E-9C89920AF985

P2860

Q36726112-029BF55B-4F7E-40F2-93BA-01B602E9C2E6

Q36726112-06ACD0CF-6F58-4046-A3D1-5B30A22AFFD7

Q36726112-0C3519E0-4406-4D73-ABDA-79C7FFAA2822

Q36726112-198D6966-6EAD-4B7C-9D4A-C7A9AF83224E

Q36726112-19A59847-C60C-47BF-9A7D-D0B121398673

Q36726112-1E32AE1F-670E-4EF1-B0AF-B6D318284434

Q36726112-1FA2BC72-27D5-4B67-90F5-3F33560851B2

Q36726112-26FAD0E1-E231-4416-983E-E0C4502C623D

Q36726112-2B849BA0-48B7-4265-88F3-11CD48B3FE07

Q36726112-2F385A37-CF6F-43D7-8360-95032E1DCE33

P304

Q36726112-5F1F53AF-264F-4567-818A-BC4FEDC5C230

P31

Q36726112-5FEABE11-BAC0-4940-A035-38E5F7C4653E

P356

Q36726112-8EE5573D-EAFB-4F1F-9BDD-002A9C771CD5

P407

Q36726112-230363AC-C0FA-472B-96AA-5D85C2638524

P433

Q36726112-792C7514-9B46-4BE9-8561-3EC8A19D7161

P478

Q36726112-5D51AF67-F020-4DBA-9983-8E3CE89FD4C6

P577

Q36726112-2511463C-C923-40B6-83BF-F033346CC466

P698

Q36726112-65FF39C0-DCBF-4157-A2FB-F9C581A2F4F8

P932

Q36726112-59DA0ADB-8627-41B3-8EB7-78A58F26E866

P356

P1433

Journal of Clinical Investigation

P1476

Acquired resistance to EGFR ty ...... y loss of IGF-binding proteins

@en

P2093

Anthony C Faber

http://www.w3.org/2001/XMLSchema#string

Brenda Seidel

http://www.w3.org/2001/XMLSchema#string

Cammie Rinehart

http://www.w3.org/2001/XMLSchema#string

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Douglas Yee

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Maria Graciela Olivares

http://www.w3.org/2001/XMLSchema#string

Marta Guix

http://www.w3.org/2001/XMLSchema#string

Sherman Qu

http://www.w3.org/2001/XMLSchema#string

Shizhen Emily Wang

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

P304

2609-2619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI34588

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18568074

http://www.w3.org/2001/XMLSchema#string

P932

2430495

http://www.w3.org/2001/XMLSchema#string